Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

De novo designed protein inhibitors of amyloid aggregation and seeding

15 Aug 2022

Abstract excerpt

Neurodegenerative diseases are characterized by the pathologic accumulation of aggregated proteins. Known as amyloid, these fibrillar aggregates include proteins such as tau and amyloid-β (Aβ) in Alzheimer’s disease (AD) and alpha-synuclein (αSyn) in Parkinson’s disease (PD). The development and spread of amyloid fibrils within the brain correlates with disease onset and progression, and inhibiting amyloid...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alzheimer's disease research and treatments
Share to Parkinson's Disease Mechanisms and Treatments
Share to Protein Structure and Dynamics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35969734
DOI: 10.1073/pnas.2206240119

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

De novo designed protein inhibitors of amyloid aggregation and seedingPMID 35969734Read ↗

Designed inhibitors to reduce amyloid virulence and cytotoxicity and combat neurodegenerative and infectious diseasesSemantic proximity Read ↗

Design of Tau Aggregation Inhibitors Using Iterative Machine Learning and a Polymorph-Specific Brain-Seeded Fibril Amplification AssaySemantic proximity Read ↗

Mitigating protein aggregation to reduce the toxicity inherent to Parkinson's and Alzheimer's diseasesSemantic proximity Read ↗

Protein misfolding, aggregation and mechanism of amyloid cytotoxicity: An overview and therapeutic strategies to inhibit aggregationSemantic proximity Read ↗

Design of amyloidogenic peptide trapsSemantic proximity Read ↗

Potent substoichiometric inhibition of alpha-synuclein aggregation by <i>de novo</i> oligomer-binding proteinsSemantic proximity Read ↗

Amyloids: The History of Toxicity and FunctionalitySemantic proximity Read ↗

Thiadiazolidinone (TDZD) Analogs Inhibit Aggregation-Mediated Pathology in Diverse Neurodegeneration Models, and Extend C. elegans Life- and HealthspanSemantic proximity Read ↗

Cryo-EM structure and inhibitor design of human IAPP (amylin) fibrilsSemantic proximity Read ↗

Ensemble-based design of tau to inhibit aggregation while preserving biological activitySemantic proximity Read ↗

FTD-tau S320F mutation stabilizes local structure and allosterically promotes amyloid motif-dependent aggregationSemantic proximity Read ↗

Structure-based inhibitors halt prion-like seeding by Alzheimer’s disease–and tauopathy–derived brain tissue samplesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.